Anakinra

This classification denotes an interleukin-1 receptor antagonist with the molecular formula C759H1186N208O232S10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9013DUQ28K, more generally known as anakinra. European Medicines Agency schedules anakinra in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05500MIG. The term ANAKINRA is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 9, no. 3, 1995, list 35. ANAKINRA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule anakinra under HS 30021095 and SITC 54163. As of Q4 2014, ANAKINRA remains the US FDA Preferred Term for this commodity. Anakinra bears US NLM identifiers UMLS ID C0245109 and NCI Concept Code C38717. SMILES: none.